oleanolic acid 3-O-monoglucuronide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 176079 |
| CHEMBL ID | 446866 |
| CHEBI ID | 37658 |
| MeSH ID | M0208571 |
| Synonym |
|---|
| momordin ib |
| oleanolic acid 3-o-glucuronide |
| CHEBI:37658 , |
| glycoside st-e |
| calenduloside e |
| oleanolic acid 3-o-beta-d-glucosiduronic acid |
| 3-o-(beta-d-glucopyranuronosyl)oleanolic acid |
| 28-hydroxy-28-oxoolean-12-en-3beta-yl beta-d-glucopyranosiduronic acid |
| oleanoic acid 3-o-glucuronide |
| silphioside f |
| C08964 |
| 26020-14-4 |
| oleanolic acid 3-o-monoglucuronide |
| (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid |
| CHEMBL446866 |
| beta-d-glucopyranosiduronic acid, (3beta)-17-carboxy-28-norolean-12-en-3-yl |
| oleanolic acid 3-o-beta-d-glucuronopyranoside |
| 184358rycu , |
| olean-12-en-28-oic acid, 3beta-(beta-d-glucopyranuronosyloxy)- |
| glucopyranosiduronic acid, 3beta-hydroxyolean-12-en-28-oic acid, beta-d- |
| unii-184358rycu |
| oleanolic acid 3-o-.beta.-d-glucuronopyranoside |
| .beta.-d-glucopyranosiduronic acid, (3.beta.)-17-carboxy-28-norolean-12-en-3-yl |
| 28-desglucosylchikusetsusaponin iva |
| glucopyranosiduronic acid, 3.beta.-hydroxyolean-12-en-28-oic acid, .beta.-d- |
| olean-12-en-28-oic acid, 3.beta.-(.beta.-d-glucopyranuronosyloxy)- |
| 3-o-(.beta.-d-glucopyranuronosyl)oleanolic acid |
| AC-34369 |
| DTXSID90180668 , |
| AKOS030528265 |
| 108322-31-2 |
| Q27104421 |
| HY-N6850 |
| CS-0100275 |
| MS-30872 |
| b-d-glucopyranosiduronic acid,(3b)-17-carboxy-28-norolean-12-en-3-yl |
| momordin b |
| calendulosidee |
| dtxcid30103159 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " In the pharmacokinetic (PK) study, beagle dogs were given oral doses of calenduloside E (1." | ( Pharmacokinetic study of calenduloside E and its active metabolite oleanolic acid in beagle dog using liquid chromatography-tandem mass spectrometry. Cheng, L; Fawcett, JP; Gu, J; Shi, M; Sun, X; Sun, Y; Xu, H; Yang, Y; Zhao, S, 2014) | 0.4 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The bioavailability of 29 was significantly improved in comparison with its aglycon." | ( Synthesis and anti-inflammatory activity of saponin derivatives of δ-oleanolic acid. Chen, C; Cheng, K; Dai, L; Hu, K; Li, H; Liu, L; Sun, H; Wen, X; Xu, Q; Yuan, H, 2021) | 0.62 |
| Class | Description |
|---|---|
| beta-D-glucosiduronic acid | A glucosiduronic acid resulting from the formal condensation of any substance with beta-D-glucuronic acid to form a glycosidic bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1235938 | Cytotoxicity against human NCI-H460 cells incubated for 72 hrs by cell-titer 96 aqueous non-radioactive cell proliferation assay | 2015 | Journal of natural products, Aug-28, Volume: 78, Issue:8 | Digging Deep for New Compounds from the Compass Plant, Silphium laciniatum. |
| AID1728066 | Activation of AMPK in human Huh-7 cells assessed as increase in AMPK phosphorylation at Thr172 residue at 10 uM measured after 12 hrs by Western blot analysis | 2021 | European journal of medicinal chemistry, Jan-01, Volume: 209 | Synthesis and anti-inflammatory activity of saponin derivatives of δ-oleanolic acid. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 1 (4.76) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 7 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 21 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||